Robotics Market is Thriving to Reach US 154.04 Billion By 2033 Astute Analytica

ALT Stock  USD 7.11  0.10  1.39%   
Slightly above 61% of Altimmune's investor base is looking to short. The analysis of the overall investor sentiment regarding Altimmune suggests that many traders are alarmed. Altimmune's investing sentiment can be driven by a variety of factors including economic data, Altimmune's earnings reports, geopolitical events, and overall market trends.
  
The robotics market is thriving, driven by technological advancements and widespread adoption across sectors. With significant investments fueling innovation and productivity, the future looks bright, promising transformative solutions that will enhance efficiency and create new opportunities in the global economy.New Delhi, Dec. 09, 2024 -- The global robotics market was valued at US 45.44 billion in 2024 and is projected to reach US 154.04 billion by 2033 at a CAGR of 14.5

Read at finance.yahoo.com
Yahoo News
  

Altimmune Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Altimmune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Altimmune Fundamental Analysis

We analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Shares Shorted

Number Of Shares Shorted Comparative Analysis

Altimmune is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Altimmune Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Altimmune stock to make a market-neutral strategy. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics with similar companies.

Peers

Altimmune Related Equities

VSTMVerastem   25.53   
0%
100.0%
SAVACassava Sciences   24.15   
0%
94.0%
AVXLAnavex Life   13.13   
0%
51.0%
RVPHReviva Pharmaceuticals   11.05   
0%
43.0%
INMBINmune Bio   6.90   
0%
27.0%
CABACabaletta Bio   5.58   
0%
21.0%
FBIOFortress Biotech   4.43   
0%
17.0%
INZYInozyme Pharma   2.89   
0%
11.0%
TERNTerns Pharmaceuticals   2.35   
0%
9.0%
VKTXViking Therapeutics   2.19   
0%
8.0%
ACADACADIA Pharmaceuticals   1.69   
0%
6.0%
MDGLMadrigal Pharmaceuticals   1.69   
0%
6.0%
HEPAHepion Pharmaceuticals   1.02   
0%
3.0%
ARDXArdelyx   0.99   
0%
3.0%
AKROAkero Therapeutics   0.93   
0%
3.0%
CGTXCognition Therapeutics   0.42   
0%
1.0%
DAWNDay One   0.32   
0%
1.0%
XFORX4 Pharmaceuticals   0.27   
0%
1.0%
ATHAAthira Pharma     
0%
1.0%
BIVIBiovie   1.83   
7.0%
0%
HOOKHookipa Pharma   2.99   
11.0%
0%
ZURAZura Bio   6.00   
23.0%
0%

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.